Trial Profile
A Phase 3 Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2019
Price :
$35
*
At a glance
- Drugs Uproleselan (Primary) ; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 06 Mar 2019 According to a GlycoMimetics media release, this trial is expected to start in 2019.
- 08 Feb 2018 According to a GlycoMimetics media release, Professor Gerwin Huls is the principal investigator at HOVON and Professor of Haematology at University Medical Centre Groningen.
- 08 Feb 2018 According to a GlycoMimetics media release, this trial is expected to start this year and will be conducted in five countries across Europe.